Study of the effect of zinc oxide, selenium, and silver nanoparticles on the expression level of oxidative stress-associated genes in ovarian cancer
- PMID: 39760958
- DOI: 10.1007/s12032-024-02593-1
Study of the effect of zinc oxide, selenium, and silver nanoparticles on the expression level of oxidative stress-associated genes in ovarian cancer
Abstract
Reactive oxygen species (ROS) generated by oxidative stress have emerged as critical factors in the pathophysiology of malignancies. This study investigated the antioxidant and anticancer properties of zinc (Zn), selenium (Se), and silver (Ag) nanoparticles (NPs) against the A2780 human ovarian cancer cell line. Here, the bioinformatics approach was used to determine the top differentially expressed genes associated with oxidative stress. The ZnO-, Se-, and Ag-NPs were then synthesized via a green synthesis method and subsequently characterized using techniques, such as FTIR, XRD, DLS, zeta potential analysis, FESEM, and TEM. The antioxidant capacity of the NPs was evaluated using a DPPH scavenging assay and their effect on superoxide dismutase enzyme activity was determined. HDF and A2780 cells were treated with varying concentrations of ZnO-, Se-, and Ag-NPs, and cell viability and colony formation were assessed using MTT and clonogenic assays, respectively. Additionally, qPCR was performed to analyze the expression of the candidate genes NOX4, SOD2, and NR4A4. Characterization techniques confirmed the successful synthesis of pure, crystalline, and spherical NPs. Antioxidant assays demonstrated the significant antioxidant properties of ZnO-, Se-, and Ag-NPs. In vitro studies indicated that ZnO-, Se-, and Ag-NPs effectively inhibited cell proliferation and suppressed colony formation, likely owing to the downregulation of NOX4 and upregulation of SOD2 genes. Our findings suggest that ZnO-, Se-, and Ag-NPs may serve as promising anticancer agents for ovarian cancer and NOX4 downregulation and SOD2 upregulation can be proposed as oxidative stress biomarkers; however, further experimental investigation is required to elucidate the therapeutic potential of NPs and the early detection potential of biomarkers.
Keywords: Ovarian cancer; Selenium nanoparticle; Silver nanoparticle; Stress-oxidative pathway; Zinc nanoparticle.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: We certify that there is no conflict of interest with any financial organization.
Similar articles
-
Dual-loaded ZnO and Se nanoparticles in chitosan/alginate bio-composite: synthesis, cytotoxicity, antioxidant activity, and anti-cervical cancer potential.3 Biotech. 2025 Aug;15(8):264. doi: 10.1007/s13205-025-04436-w. Epub 2025 Jul 22. 3 Biotech. 2025. PMID: 40708852
-
Biosynthesis and Characterization of Termites Wings Extract Derived Silver, Zinc, and Silver-Doped Zinc Oxide Nanoparticles for Antioxidant and Anticancer Activity.Chem Biodivers. 2025 Jul;22(7):e202402466. doi: 10.1002/cbdv.202402466. Epub 2025 Mar 21. Chem Biodivers. 2025. PMID: 40024893
-
Zinc oxide nanoparticles induce apoptosis and autophagy in human ovarian cancer cells.Int J Nanomedicine. 2017 Sep 5;12:6521-6535. doi: 10.2147/IJN.S140071. eCollection 2017. Int J Nanomedicine. 2017. PMID: 28919752 Free PMC article.
-
Investigating antioxidant effects of hamamelitannin-conjugated zinc oxide nanoparticles on oxidative stress-Induced neurotoxicity in zebrafish larvae model.Mol Biol Rep. 2024 Oct 22;51(1):1087. doi: 10.1007/s11033-024-09998-1. Mol Biol Rep. 2024. PMID: 39436450
-
Selenium Nanoparticles as Neuroprotective Agents: Insights into Molecular Mechanisms for Parkinson's Disease Treatment.Mol Neurobiol. 2025 Jun;62(6):6655-6682. doi: 10.1007/s12035-024-04253-x. Epub 2024 Jun 5. Mol Neurobiol. 2025. PMID: 38837103 Review.
Cited by
-
Nanocarrier drug delivery systems for gynecological cancer therapeutics.J Control Release. 2025 Sep 10;385:114028. doi: 10.1016/j.jconrel.2025.114028. Epub 2025 Jul 17. J Control Release. 2025. PMID: 40683601 Review.
References
-
- Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020. https://doi.org/10.1136/bmj.m3773 . - DOI - PubMed
-
- Sahoo BM, Banik BK, Borah P, Jain A. Reactive oxygen species (ROS): key components in cancer therapies. Anti-Cancer Agents Med Chem. 2022;22(2):215–22.
-
- Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016;2(1):1–22.
-
- Yang F, Jin C, Jiang Y, Li J, Di Y, Ni Q, et al. Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside. Cancer Treat Rev. 2011;37(8):633–42. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical